Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering AAV capsids.

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.

Ocuphire Pharma has acquired Opus Genetics, creating a new entity focused on gene therapies, which will trade as Opus ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important ...